GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (OTCPK:OBIMF) » Definitions » LT-Debt-to-Total-Asset

OBIMF (Ondine Biomedical) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Ondine Biomedical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ondine Biomedical's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

Ondine Biomedical's long-term debt to total assets ratio declined from Jun. 2023 (0.04) to Jun. 2024 (0.00). It may suggest that Ondine Biomedical is progressively becoming less dependent on debt to grow their business.

Ondine Biomedical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Ondine Biomedical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical LT-Debt-to-Total-Asset Chart

Ondine Biomedical Annual Data
Trend Dec08 Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.03 - 0.03 0.03

Ondine Biomedical Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.04 0.03 -

Ondine Biomedical LT-Debt-to-Total-Asset Calculation

Ondine Biomedical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0.119/4.274
=0.03

Ondine Biomedical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=0/2.937
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical  (OTCPK:OBIMF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ondine Biomedical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Ondine Biomedical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (OTCPK:OBIMF) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
AQSE:INC LSE:AREC LSE:ONC LSE:HEMO LSE:SAR LSE:SBTX LSE:OPTI LSE:IXI LSE:POLB LSE:SNG VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
OBI:UK VF5:Germany
Address
1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Website
https://www.ondinebio.com
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.